NanoString Launches nCounter Antibody Drug Conjugate Panel to Accelerate the Development of Oncology Treatments

Rhea-AI Summary

NanoString Technologies, a leader in life science tools, has launched the nCounter® ADC Development Panel to facilitate research in Antibody Drug Conjugates (ADCs). This new gene expression tool, developed with input from pharmaceutical experts, aims to provide comprehensive molecular insights necessary for addressing critical questions in oncology therapies. The panel can profile 770 genes and aids in understanding ADC mechanisms, including tumor targeting and resistance. Currently, there are 10 approved ADCs and over 80 in clinical trials, indicating the growing importance of this technology in cancer treatment.

Positive

• Launch of the nCounter® ADC Development Panel enhances NanoString's product offerings in the ADC field.
• Panel allows profiling of 770 genes, addressing critical biological questions and enhancing research capabilities.
• Increased market relevance as ADCs gain traction in cancer therapies, with 10 approved drugs and over 80 in trials.

Negative

• None.

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter® ADC Development Panel, a specialized gene expression tool for use in the rapidly expanding field of Antibody Drug Conjugates (ADCs). Created in collaboration with leading pharmaceutical and clinical scientists, this novel panel is designed to provide molecular insights into important biological questions and challenges of oncology therapies.

Image of an Antibody Drug Conjugates (ADCs) enabling the targeted delivery of highly potent cytotoxic compounds to treat cancer. (Photo: Business Wire)

ADCs are defined as a new class of highly potent therapeutics composed of an antibody attached via a chemical linker to a biologically active drug or cytotoxic compound. These targeted agents allow for sensitive discrimination between healthy and cancer tissues with the cell-killing ability of cytotoxic drugs. The field now has 10 approved drugs, over 80 investigational ADCs, and nearly 200 clinical trials and is gaining momentum as an effective approach for targeting cancer.

The new panel provides for customizable ADC content to address complex questions critical for the success of Antibody Drug Conjugates throughout discovery, pre-clinical and clinical development. The panel can be used to directly profile 770 genes addressing essential biological questions relevant to each step in the ADC development workflow, including tumor targeting and antigen expression; ADC internalization; payload release; drug mechanisms of action; target cell death; immunogenic cell death; and mechanisms of resistance.

"With this panel, researchers have a powerful, cutting-edge tool that addresses biological function with deep molecular characterization, expanding insights gained from traditional endpoint assays," said Joseph Beechem, Chief Scientific Officer at NanoString. "The specific and sophisticated characterization will allow us to fully understand mechanisms of action, potential resistance, as well as the role of the immune response."

To learn more about how NanoString is addressing the challenges within the field of ADC, visit NanoString at the virtual World ADC Conference Oct. 11-14. On Oct. 12, NanoString will present "Optimizing ADC Development and Patient-Treatment Selection," led by Dr. Funda Meric-Bernstam, the Chair of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center.

About NanoString Technologies, Inc.

NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company's nCounter® Analysis System is used in life sciences research and has been cited in more than 4,900 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's GeoMx® Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.

For more information, please visit www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005285/en/

Doug Farrell, NanoString

Vice President, Investor Relations & Corporate Communications

dfarrell@nanostring.com

Phone: 206-602-1768

Source: NanoString Technologies, Inc.

FAQ

What is the nCounter® ADC Development Panel launched by NanoString Technologies?

The nCounter® ADC Development Panel is a gene expression tool designed for research in Antibody Drug Conjugates (ADCs), providing insights into oncology therapies.

How does the nCounter® ADC Development Panel enhance ADC research?

The panel profiles 770 genes, addressing key biological questions related to ADC mechanisms, including tumor targeting and resistance.

What are the current market dynamics for Antibody Drug Conjugates?

There are currently 10 approved ADCs and over 80 investigational ADCs in clinical trials, reflecting the growing relevance of this treatment approach.

Who contributed to the development of the nCounter® ADC Development Panel?

The panel was developed in collaboration with leading pharmaceutical and clinical scientists.

When was the nCounter® ADC Development Panel launched?

NanoString Technologies launched the nCounter® ADC Development Panel on October 12.